Loading…
Based on limited metadata with no full letter text available, this FDA Warning Letter issued to Namsa in March 2018 addresses compliance concerns for a product or service category listed as "Other," indicating the violations fall outside standard device or drug classifications. Without access to the subject line or specific violation details, the exact nature of the regulatory concerns cannot be determined from the available information. The issuing office is not specified in the metadata provided, limiting clarity on which FDA division initiated the warning.